Table 1 Baseline characteristics of patients with hepatocellular carcinoma in this study and in the original SNACOR study [7]
This study | Original SNACOR study | ||||
|---|---|---|---|---|---|
n = 268 | % | n = 340 | % | ||
Prior to first TACE | |||||
Age, y | Mean ± SD | 66.5 ± 9.4 | 58 | ||
Range | 36.1–87.3 | 51–65 | |||
Sex | Male | 227 | 84.7 | 274 | 80.6 |
Female | 41 | 15.3 | 66 | 19.4 | |
Aetiologya | Alcohol | 134 | 50.0 | ||
Hepatitis B virus | 24 | 9.0 | 242 | 71.2 | |
Hepatitis C virus | 77 | 28.7 | 44 | 12.9 | |
Otherb | 42 | 15.7 | 54 | 15.9 | |
No underlying liver disease | 9 | 3.3 | 0 | 0 | |
Child Pugh stage | A | 184 | 68.7 | 288 | 84.7 |
B | 84 | 31.3 | 52 | 15.3 | |
Tumour size, mm | Mean ± SD | 52 ± 35 | 53 | ||
Range | 10–215 | 27–88 | |||
Number of nodes | 1 | 78 | 29.1 | 127 | 37.4 |
2 | 80 | 29.9 | 74 | 21.8 | |
3 | 44 | 16.4 | 31 | 9.1 | |
4 | 36 | 13.4 | 31 | 9.1 | |
≥5 | 30 | 11.2 | 77 | 22.6 | |
Alpha–fetoprotein, ng/ml | Median | 30.5 | 120.0 | ||
Range | 0.5–920,910 | 17.1–1430.0 | |||